Amarin pushes back sales team ramp-up as Vascepa label decision nears
admin 5th November 2019 Uncategorised 0Everything is coming up aces for Amarin with prescriptions of its fish-oil derivative Vascepa through the roof and a game-changing FDA approval on the horizon. But the company’s ambitious plan to mass-market its new Vascepa approval—if and when it comes—is running a bit behind schedule.
More: Amarin pushes back sales team ramp-up as Vascepa label decision nears
Source: fierce